Tag Archives: LDL-C

Hypertriglyceridaemia: apoC-III inhibition comes of age Professor Maciej Banach (Medical University of Łódź, Poland) Professor Maciej Banach (Medical University of Łódź, Poland) opened with Olezarsen, an antisense oligonucleotide targeting APOC3 messenger RNA that accelerates clearance of triglyceride-rich remnants. In ESSENCE-TIMI 73b (phase 3, n=1,349), it lowered triglycerides by around 60% at six months in moderate hypertriglyceridaemia, with most patients reaching a level below 1.7 mmol/L.1 In the separate CORE-TIMI 72a and CORE2-TIMI 72b trials in severe hypertriglyceridaemia, adjudicated acute pancreatitis was significantly les

The BEACON Steering Committee The Bringing Education and Awareness to Cholesterol Optimisation Needs (BEACON) steering committee comprises a multidisciplinary group of healthcare professionals that aims to provide education and advice regarding lipid management, including the streamlining of associated pathways, in clinical practice across the UK. The group is committed to the development of educational resources that will support care providers and help to reshape and align current processes, improve knowledge and enable greater understanding of the rapidly changing lipid-lowering treatment pathway as new therapies become available.

Familial hypercholesterolaemia or not? The importance of considering polygenic hypercholesterolaemia in those with no monogenic cause for familial hypercholesterolaemia (FH), was outlined by Professor Steve Humphries (UCL Institute of Cardiovascular Science, London).1 By looking for the presence of specific high low-density lipoprotein cholesterol (LDL-C), single nucleotide polymorphisms (SNPs) and combining these to generate a SNP-score, those with the most variants can be identified. Professor Steve Humphries Individuals who are in the top five deciles of the SNP-score are highly likely to have a polygenic explanation for their high LDL-C

Data presented at the recent American Heart Association Scientific Sessions 2020, showed pooled results from three ORION phase III trials in more than 3,600 patients with atherosclerotic cardiovascular disease (or heterozygous familial hypercholesterolemia (HeFH), who were given inclisiran at months 1, 3 and then every 6 months up to month 17. Results of the first analysis showed LDL-C reductions of approximately 51% from baseline for both women and men at 17 months. A second analysis demonstrated treatment with inclisiran lowered LDL-C similarly by approximately 51% across three age groups (<65, ≥65 to <75, and ≥75 years old). In b